Printed from https://ideas.repec.org/s/spr/aphecp5.html
Content
June 2016, Volume 14, Issue 3
- 323-335 Cost and Budget Impact Analysis of an Accurate Intraoperative Sentinel Lymph Node Diagnosis for Breast Cancer Metastasis
by Yuko Saruta & Jaume Puig-Junoy - 337-347 Measuring Efficiency of Health Systems of the Middle East and North Africa (MENA) Region Using Stochastic Frontier Analysis
by Samer Hamidi & Fevzi Akinci - 349-359 The Role of Physician Recommendations and Public Policy in Human Papillomavirus Vaccinations
by Ali Moghtaderi & Scott Adams - 375-385 Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making
by Takeru Shiroiwa & Shinya Saito & Kojiro Shimozuma & Satoshi Kodama & Shinichi Noto & Takashi Fukuda
April 2016, Volume 14, Issue 2
- 127-128 A Review of “The New Drug Reimbursement Game: A Regulator’s Guide to Playing and Winning”
by Christopher J. McCabe - 135-149 Tegaderm CHG IV Securement Dressing for Central Venous and Arterial Catheter Insertion Sites: A NICE Medical Technology Guidance
by Michelle Jenks & Joyce Craig & William Green & Neil Hewitt & Mick Arber & Andrew Sims - 151-159 A Scoping Review of Healthcare Costs for Patients with Cystic Fibrosis
by Ilene L. Hollin & Karen A. Robinson - 161-183 A Systematic Review of the Literature on the Development of Condition-Specific Preference-Based Measures of Health
by Elizabeth Goodwin & Colin Green - 185-193 The Cost Effectiveness of High-Dose versus Conventional Haemodialysis: a Systematic Review
by S. Laplante & F. X. Liu & B. Culleton & A. Bernardo & Denise King & P. Hudson - 195-204 Household Size and the Decision to Purchase Health Insurance in Cambodia: Results of a Discrete-Choice Experiment with Scale Adjustment
by Sachiko Ozawa & Simrun Grewal & John F.P. Bridges - 205-215 The Long-Term Cost to the UK NHS and Social Services of Different Durations of IV Thiamine (Vitamin B1) for Chronic Alcohol Misusers with Symptoms of Wernicke’s Encephalopathy Presenting at the Emergency Department
by Edward C. F. Wilson & George Stanley & Zulfiquar Mirza - 217-227 Formal Professional Relationships Between General Practitioners and Specialists in Shared Care: Possible Associations with Patient Health and Pharmacy Costs
by Ágnes Lublóy & Judit Lilla Keresztúri & Gábor Benedek - 229-240 Effectiveness and Cost of a Personalized Reminder Intervention to Improve Adherence to Glaucoma Care
by Laura T. Pizzi & Judie Tran & Anousheh Shafa & Michael Waisbourd & Lisa Hark & Ann P. Murchison & Yang Dai & Eileen L. Mayro & Julia A. Haller - 241-241 Comment on: “The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011”
by Afschin Gandjour - 243-243 Authors’ Reply to Gandjour: “The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011”
by Kenneth E. Thorpe & Lindsay Allen & Peter Joski
February 2016, Volume 14, Issue 1
- 9-20 Why ‘Optimal’ Payment for Healthcare Providers Can Never be Optimal Under Community Rating
by Peter Zweifel & H. E. Frech - 29-40 Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA
by Axel C. Mühlbacher & Anika Kaczynski - 77-87 Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation
by Ataru Igarashi & Rei Goto & Kiyomi Suwa & Reiko Yoshikawa & Alexandra J. Ward & Jörgen Moller - 89-104 Comparison of Modes of Administration and Alternative Formats for Eliciting Societal Preferences for Burden of Illness
by Donna Rowen & John Brazier & Anju Keetharuth & Aki Tsuchiya & Clara Mukuria - 117-118 Comment on: “Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists”
by Carl Samuelsen & Eric D. Bateman & Ian Pavord & Adam Lloyd & Mike Baldwin & Dirk Esser - 119-125 Erratum to: Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists
by Jenny Willson & Eric D. Bateman & Ian Pavord & Adam Lloyd & Tania Krivasi & Dirk Esser
December 2015, Volume 13, Issue 6
- 557-565 Improving Cross-Sector Comparisons: Going Beyond the Health-Related QALY
by John Brazier & Aki Tsuchiya - 567-581 Estimating the Costs of Torture: Challenges and Opportunities
by Emmanuel Mpinga & Ngianga-Bakwin Kandala & Jennifer Hasselgård-Rowe & Félicien Tshimungu Kandolo & Henk Verloo & Ngoyi Bukonda & Philippe Chastonay - 583-594 The Debrisoft ® Monofilament Debridement Pad for Use in Acute or Chronic Wounds: A NICE Medical Technology Guidance
by Catherine Meads & Eleonora Lovato & Louise Longworth - 595-613 A Systematic Review of the State of Economic Evaluation for Health Care in India
by Shankar Prinja & Akashdeep Chauhan & Blake Angell & Indrani Gupta & Stephen Jan - 615-626 The Role of Information Provision in Economic Evaluations of Newborn Bloodspot Screening: A Systematic Review
by Stuart Wright & Cheryl Jones & Katherine Payne & Nimarta Dharni & Fiona Ulph - 627-635 Hospital Utilization and Universal Health Insurance Coverage: Evidence from the Massachusetts Health Care Reform Act
by Attila Cseh & Brandon Koford & Ryan Phelps - 637-645 Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden
by Madlaina Costa-Scharplatz & Björn Ställberg & Pankaj Goyal & Yumi Asukai & Jean-Bernard Gruenberger & David Price - 647-659 Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study
by Renee Lévesque & Daniele Marcelli & Héloïse Cardinal & Marie-Line Caron & Muriel Grooteman & Michiel Bots & Peter Blankestijn & Menso Nubé & Aileen Grassmann & Bernard Canaud & Afschin Gandjour
October 2015, Volume 13, Issue 5
- 433-435 Medicare’s Mission to Change How Health Care is Paid for and Delivered: A Cloud with a Silver Lining or Just a Dark Cloud?
by Jeffrey Voigt - 437-443 Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement
by Stavros Petrou & Oliver Rivero-Arias & Helen Dakin & Louise Longworth & Mark Oppe & Robert Froud & Alastair Gray - 445-456 Vision Amniotic Leak Detector (ALD) to Eliminate Amniotic Fluid Leakage as a Cause of Vaginal Wetness in Pregnancy: A NICE Medical Technology Guidance
by A. Ray & S. Peirce & A. Wilkes & G. Carolan-Rees - 457-467 A Systematic Review of Economic Evaluations of the Use of Robotic Assisted Laparoscopy in Surgery Compared with Open or Laparoscopic Surgery
by Zafer Tandogdu & Luke Vale & Cynthia Fraser & Craig Ramsay - 469-483 A Systematic Review and Narrative Synthesis of Health Economic Studies Conducted for Hereditary Haemochromatosis
by Barbara Graaff & Amanda Neil & Kristy Sanderson & Lei Si & Kwang Yee & Andrew Palmer - 485-492 Valuing Child Health Utility 9D Health States with Young Adults: Insights from a Time Trade Off Study
by Julie Ratcliffe & Gang Chen & Katherine Stevens & Sandra Bradley & Leah Couzner & John Brazier & Michael Sawyer & Rachel Roberts & Elisabeth Huynh & Terry Flynn - 493-506 A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda
by Solomon Lubinga & Byamah Mutamba & Angelo Nganizi & Joseph Babigumira - 507-514 The Robustness and Effectiveness of the Triage System at Times of Overcrowding and the Extra Costs due to Inappropriate Use of Emergency Departments
by Paolo Cremonesi & Enrico Bella & Marcello Montefiori & Luca Persico - 515-523 An Interrupted Time-Series Analysis to Assess Impact of Introduction of Co-Payment on Emergency Room Visits in Cyprus
by Panagiotis Petrou - 525-542 Cost-Effectiveness of School-Based Prevention of Cannabis Use
by Charlotte Deogan & Natalie Zarabi & Nils Stenström & Pi Högberg & Eva Skärstrand & Edison Manrique-Garcia & Kristian Neovius & Anna Månsdotter - 543-551 Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population
by Gemma Shields & Alexander Bates & Ann-Marie Chapman
August 2015, Volume 13, Issue 4
- 311-313 The Value of Productivity in Health Policy
by Wilbert Van den Hout - 315-324 VibraTip™ for Testing Vibration Perception to Detect Diabetic Peripheral Neuropathy: A NICE Medical Technology Guidance
by Iain Willits & Helen Cole & Roseanne Jones & Paul Dimmock & Mick Arber & Joyce Craig & Andrew Sims - 325-340 A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection
by Jonathon Campbell & Thenuga Sasitharan & Fawziah Marra - 341-357 US and International In-Hospital Costs of Extracorporeal Membrane Oxygenation: a Systematic Review
by Michael Harvey & Michael Gaies & Lisa Prosser - 359-367 Productivity Losses Associated with Head and Neck Cancer Using the Human Capital and Friction Cost Approaches
by Alison Pearce & Paul Hanly & Aileen Timmons & Paul Walsh & Ciaran O’Neill & Eleanor O’Sullivan & Rachael Gooberman-Hill & Audrey Thomas & Pamela Gallagher & Linda Sharp - 369-379 Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis
by Santiago Grau & Virginia Lozano & Amparo Valladares & Rafael Cavanillas & Yang Xie & Gonzalo Nocea - 381-387 The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011
by Kenneth Thorpe & Lindsay Allen & Peter Joski - 389-397 Equitable Prices of Single-Source Drugs in Thailand
by Surachat Ngorsuraches & Kanokkan Chaiyakan - 399-407 Health Economic Evaluation of a Strict Glucose Control Guideline Implemented Using Point-of-Care Testing in Three Intensive Care Units in The Netherlands
by Roosmarijn Hooijdonk & Lotte Steuten & Michelle Kip & Helma Monteban & Marianne Mulder & Floris Braam Houckgeest & Johannes Sluijs & Ameen Abu-Hanna & Peter Spronk & Marcus Schultz - 409-420 A Comparison of Japan and UK SF-6D Health-State Valuations Using a Non-Parametric Bayesian Method
by Samer Kharroubi - 421-432 Cost Effectiveness of Using Array-CGH for Diagnosing Learning Disability
by G. Sagoo & S. Mohammed & G. Barton & G. Norbury & J. Ahn & C. Ogilvie & M. Kroese
June 2015, Volume 13, Issue 3
- 265-267 An Economist’s Influence on Health Policy
by Peter Zweifel - 269-271 Cost-Effectiveness Analysis: A View into the Abyss
by Paul Kind - 273-279 How do Economic Evaluations Inform Health Policy Decisions for Treatment and Prevention in Canada and the United States?
by Don Husereau & Anthony Culyer & Peter Neumann & Philip Jacobs - 281-289 Health Economics and Health Policy: Experiences from New Zealand
by Jacqueline Cumming - 291-302 Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice?
by George Dranitsaris & George Papadopoulos - 303-309 Bridging the Gap: Exploring the Barriers to Using Economic Evidence in Healthcare Decision Making and Strategies for Improving Uptake
by Gregory Merlo & Katie Page & Julie Ratcliffe & Kate Halton & Nicholas Graves
April 2015, Volume 13, Issue 2
- 121-123 The Case of Penny Wise but Access and Quality of Care Foolish
by Jeffrey Voigt - 125-127 Biosimilar Versus Generic Drugs: Same But Different?
by Katelijne Vooren & Alessandro Curto & Livio Garattini - 129-133 Measuring the Cost Effectiveness of HIV Prevention Interventions in the US: Pitfalls and Problems
by Fred Hellinger - 135-147 The geko™ Electro-Stimulation Device for Venous Thromboembolism Prophylaxis: A NICE Medical Technology Guidance
by Jennifer Summers & James Clinch & Muralikrishnan Radhakrishnan & Andy Healy & Viktoria McMillan & Elizabeth Morris & Tiago Rua & Mercy Ofuya & Yanzhong Wang & Paul Dimmock & Cornelius Lewis & Janet Peacock & Stephen Keevil - 149-156 A Systematic Review on Cost Effectiveness of HIV Prevention Interventions in the United States
by Ya-Lin Huang & Arielle Lasry & Angela Hutchinson & Stephanie Sansom - 157-166 Funding, Coverage, and Access Under Thailand’s Universal Health Insurance Program: An Update After Ten Years
by Kannika Damrongplasit & Glenn Melnick - 167-179 Cost-Effectiveness and Value of Information Analysis of Nutritional Support for Preventing Pressure Ulcers in High-risk Patients: Implement Now, Research Later
by Haitham Tuffaha & Shelley Roberts & Wendy Chaboyer & Louisa Gordon & Paul Scuffham - 181-192 Opioid Misuse Among Adolescents: New Evidence from a Misclassification Analysis
by Sean Murphy & Daniel Friesner & Robert Rosenman - 193-205 Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study
by Georg Heinze & Milan Hronsky & Berthold Reichardt & Christoph Baumgärtel & Marcus Müllner & Anna Bucsics & Wolfgang Winkelmayer - 207-222 The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997–2010
by Frank Lichtenberg - 223-231 An Estimation of the Value of Informal Care Provided to Dependent People in Spain
by Juan Oliva-Moreno & Luz Peña-Longobardo & Cristina Vilaplana-Prieto - 233-242 Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism
by C. Rubio-Terrés & J. Soria & P. Morange & J. Souto & P. Suchon & J. Mateo & N. Saut & D. Rubio-Rodríguez & J. Sala & A. Gracia & S. Pich & E. Salas - 243-251 A Prediction Model of Childhood Immunization Rates
by Elizabeth Crouch & Lori Dickes - 253-263 Prospective Randomized Controlled Trial Comparing the Outcomes and Costs of Two Eyecare Adherence Interventions in Diabetes Patients
by Laura Pizzi & Camila Zangalli & Ann Murchison & Nicole Hale & Lisa Hark & Yang Dai & Benjamin Leiby & Julia Haller
August 2015, Volume 13, Issue 1
- 3-4 Safety and Quality of Generic Drugs: A Never Ending Debate Fostered by Economic Interests?
by Livio Garattini & Katelijne Vooren - 5-11 Definition and Classification of Generic Drugs Across the World
by Rafael Alfonso-Cristancho & Tatiana Andia & Tatiana Barbosa & Jonathan Watanabe - 13-20 A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators
by Shanlian Hu & Yabing Zhang & Jiangjiang He & Lixia Du & Mingfei Xu & Chunyan Xie & Ying Peng & Linan Wang - 21-33 The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review
by H. Gothe & I. Schall & K. Saverno & M. Mitrovic & A. Luzak & D. Brixner & U. Siebert - 35-45 A Systematic Review of Physicians’ and Pharmacists’ Perspectives on Generic Drug Use: What are the Global Challenges?
by Else-Lydia Toverud & Katrin Hartmann & Helle Håkonsen
February 2015, Volume 13, Issue 1
- 1-6 Systematic Overuse of Healthcare Services: A Conceptual Model
by Najlla Nassery & Jodi Segal & Eva Chang & John Bridges - 7-13 Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants
by Simon Eckermann - 15-27 A Review of the Economic Tools for Assessing New Medical Devices
by Joyce Craig & Louise Carr & John Hutton & Julie Glanville & Cynthia Iglesias & Andrew Sims - 29-45 Cost Effectiveness of Transcatheter Aortic Valve Replacement Compared with Medical Management or Surgery for Patients with Aortic Stenosis
by Andrea Iannaccone & Thomas Marwick - 47-59 Biosimilar Versus Patented Erythropoietins: Learning from 5 Years of European and Japanese Experience
by François Bocquet & Pascal Paubel & Isabelle Fusier & Anne-Laure Cordonnier & Martine Sinègre & Claude Le Pen - 61-68 Direct Costs of Unintended Pregnancy in the Russian Federation
by Julia Lowin & James Jarrett & Maria Dimova & Victoria Ignateva & Vitaly Omelyanovsky & Anna Filonenko - 69-80 Healthcare Costs Associated with Antiretroviral Adherence Among Medicaid Patients
by Zachary Pruitt & John Robst & Barbara Langland-Orban & Robert Brooks - 81-94 Comparing Willingness to Pay for Improved Drinking-Water Quality Using Stated Preference Methods in Rural and Urban Kenya
by Roy Brouwer & Fumbi Job & Bianca Kroon & Richard Johnston - 95-107 Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening
by Warner Huh & Erin Williams & Joice Huang & Tommy Bramley & Nick Poulios - 109-120 Migraine-Related Healthcare Resource Use and Costs for Subjects Prescribed Fixed-Dose Combination Sumatriptan/Naproxen Sodium vs. Single-Entity Oral Triptans in a Managed Care Population in the USA
by M. Runken & Bridgett Goodwin & Manan Shah & Michael Eaddy & Anna D’Souza & Brian Bowers & Christopher Bell
December 2014, Volume 12, Issue 6
- 573-585 Using Decision Trees to Manage Hospital Readmission Risk for Acute Myocardial Infarction, Heart Failure, and Pneumonia
by John Hilbert & Scott Zasadil & Donna Keyser & Pamela Peele - 587-599 The MAGEC System for Spinal Lengthening in Children with Scoliosis: A NICE Medical Technology Guidance
by Michelle Jenks & Joyce Craig & Joanne Higgins & Iain Willits & Teresa Barata & Hannah Wood & Christine Kimpton & Andrew Sims - 601-610 Willingness to Pay for Health Insurance Among HIV-Positive Patients in India
by Indrani Gupta & Mayur Trivedi - 611-622 Cost Effectiveness of Renal Denervation Therapy for the Treatment of Resistant Hypertension in the UK
by Daniel Gladwell & Thea Henry & Mark Cook & Ron Akehurst - 623-633 The Importance of Proximity to Death in Modelling Community Medication Expenditures for Older People: Evidence From New Zealand
by Patrick Moore & Kathleen Bennett & Charles Normand - 635-645 Direct and Indirect Economic Consequences of Multiple Sclerosis in Ireland
by Emer Fogarty & Cathal Walsh & Christopher McGuigan & Niall Tubridy & Michael Barry - 647-659 Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands
by Aikaterini Vellopoulou & Michel Agthoven & Annemarie Kolk & Robert Knegt & Gilles Berdeaux & Sandrine Cure & Florence Bianic & Mark Lamotte
October 2014, Volume 12, Issue 5
- 471-476 Ethical Objections Against Including Life-Extension Costs in Cost-Effectiveness Analysis: A Consistent Approach
by Afschin Gandjour & Dirk Müller - 477-484 EXOGEN Ultrasound Bone Healing System for Long Bone Fractures with Non-Union or Delayed Healing: A NICE Medical Technology Guidance
by Ailish Higgins & Matthew Glover & Yaling Yang & Susan Bayliss & Catherine Meads & Joanne Lord - 485-495 E-Vita Open Plus for Treating Complex Aneurysms and Dissections of the Thoracic Aorta: A NICE Medical Technology Guidance
by Muralikrishnan Radhakrishnan & Janet Peacock & Tiago Rua & Rachel Clough & Mercy Ofuya & Yanzhong Wang & Elizabeth Morris & Cornelius Lewis & Stephen Keevil - 497-510 What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer
by M. Barbieri & H. Weatherly & R. Ara & H. Basarir & M. Sculpher & R. Adams & H. Ahmed & C. Coles & T. Guerrero-Urbano & C. Nutting & M. Powell - 511-522 Examining the Influence of Antenatal Care Visits and Skilled Delivery on Neonatal Deaths in Ghana
by Monica Lambon-Quayefio & Nkechi Owoo - 523-535 Diagnostic Needle Arthroscopy and the Economics of Improved Diagnostic Accuracy: A Cost Analysis
by Jeffrey Voigt & Michael Mosier & Bryan Huber - 537-546 The Impact on Health Outcomes and Healthcare Utilisation of Switching to Generic Medicines Consequent to Reference Pricing: The Case of Lamotrigine in New Zealand
by Charon Lessing & Toni Ashton & Peter Davis - 547-557 Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases
by Brian Seal & Sean Sullivan & Scott Ramsey & Carl Asche & Ken Shermock & Syam Sarma & Erin Zagadailov & Eileen Farrelly & Michael Eaddy - 559-560 Comment on: “Insulin Glargine in a Brazilian State: Should the Government Disinvest?”
by Domingos Malerbi - 561-563 Authors’ Reply to Dr. Malerbi: “Insulin Glargine in a Brazilian State: Should the Government Disinvest?”
by Ana Souza & Francisco de Acurcio & Augusto Guerra Júnior & Renata Nascimento & Brian Godman & Leonardo Diniz - 565-565 Comment on: “Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers”
by Alessandro Curto & Livio Garattini - 567-568 Authors’ Reply to Curto and Garattini: “Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers”
by Josh Carlson & Katie Gries & Kai Yeung & Sean Sullivan & Louis Garrison
August 2014, Volume 12, Issue 4
- 347-357 Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? The Role of NICE’s Medical Technologies Evaluation Programme (MTEP)
by A. Chapman & C. Taylor & A. Girling - 359-372 A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder
by Syed Mohiuddin - 373-389 Economic Evaluations of Guideline-Based or Strategic Interventions for the Prevention or Treatment of Chronic Wounds
by Marissa Carter - 391-408 Systematic Review of the Cost Effectiveness of Radiation Therapy for Prostate Cancer from 2003 to 2013
by Neha Amin & David Sher & Andre Konski - 409-420 Peritoneal Dialysis and In-Centre Haemodialysis: A Cost-Utility Analysis from a UK Payer Perspective
by Catrin Treharne & Frank Liu & Murat Arici & Lydia Crowe & Usman Farooqui - 421-433 Disease-Specific Impoverishment Impact of Out-of-Pocket Payments for Health Care: Evidence from Rural Bangladesh
by Syed Hamid & Syed Ahsan & Afroza Begum - 435-446 Estimating the Costs of Opioid Abuse and Dependence from an Employer Perspective: a Retrospective Analysis Using Administrative Claims Data
by J. Rice & Noam Kirson & Amie Shei & Alice Cummings & Katharine Bodnar & Howard Birnbaum & Rami Ben-Joseph - 447-459 Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists
by Jenny Willson & Eric Bateman & Ian Pavord & Adam Lloyd & Tania Krivasi & Dirk Esser - 461-470 The Impact of Rural Health Care Accessibility on Cancer-Related Behaviors and Outcomes
by Eric Belasco & Gordon Gong & Barbara Pence & Ethan Wilkes
June 2014, Volume 12, Issue 3
- 231-238 Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers
by Josh Carlson & Katharine Gries & Kai Yeung & Sean Sullivan & Louis Garrison - 239-253 Modelling the Economics of Type 2 Diabetes Mellitus Prevention: A Literature Review of Methods
by P. Watson & L. Preston & H. Squires & J. Chilcott & A. Brennan - 255-265 WatchBP Home A for Opportunistically Detecting Atrial Fibrillation During Diagnosis and Monitoring of Hypertension: A NICE Medical Technology Guidance
by Iain Willits & Kim Keltie & Joyce Craig & Andrew Sims - 267-277 A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men
by Yeshi Mikyas & Irene Agodoa & Nicole Yurgin - 279-287 Paying for Formerly Free Medicines in Spain After 1 Year of Co-Payment: Changes in the Number of Dispensed Prescriptions
by Jaume Puig-Junoy & Santiago Rodríguez-Feijoó & Beatriz Lopez-Valcarcel - 289-297 Modelling Cost Effectiveness in Neovascular Age-Related Macular Degeneration: The Impact of Using Contrast Sensitivity vs. Visual Acuity
by Thomas Butt & Praveen Patel & Adnan Tufail & Gary Rubin - 299-313 Healthcare Use and Voluntary Health Insurance After Retirement in Thailand
by Papar Kananurak - 315-326 Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis
by François Bocquet & Pascal Paubel & Isabelle Fusier & Anne-Laure Cordonnier & Claude Pen & Martine Sinègre - 327-334 Belief Elicitation to Populate Health Economic Models of Medical Diagnostic Devices in Development
by Wieke Haakma & Lotte Steuten & Laura Bojke & Maarten IJzerman - 335-346 Assessing Medication Adherence and Healthcare Utilization and Cost Patterns Among Hospital-Discharged Patients with Schizoaffective Disorder
by Sudeep Karve & Michael Markowitz & Dong-Jing Fu & Jean-Pierre Lindenmayer & Chi-Chuan Wang & Sean Candrilli & Larry Alphs
April 2014, Volume 12, Issue 2
- 95-102 Managing Healthcare Budgets in Times of Austerity: The Role of Program Budgeting and Marginal Analysis
by Craig Mitton & Francois Dionne & Cam Donaldson - 103-115 Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia
by Ursula Rochau & Ruth Schwarzer & Beate Jahn & Gaby Sroczynski & Martina Kluibenschaedl & Dominik Wolf & Jerald Radich & Diana Brixner & Guenther Gastl & Uwe Siebert - 117-124 Variation in the Spillover Effects of Illness on Parents, Spouses, and Children of the Chronically Ill
by Tara Lavelle & Eve Wittenberg & Kara Lamarand & Lisa Prosser - 125-137 A Cross-Sectional Study to Evaluate the Awareness and Attitudes of Physicians Towards Reducing the Cost of Prescription Drugs, Mumbai
by Gauri Billa & Karan Thakkar & Sarita Jaiswar & Dinesh Dhodi - 139-150 The Impact of Overweight and Obesity on Pediatric Medical Expenditures
by Davene Wright & Lisa Prosser - 151-163 Cost-Utility Analysis Comparing Heavy-Weight and Light-Weight Mesh in Laparoscopic Surgery for Unilateral Inguinal Hernias
by Dmitrij Achelrod & Tom Stargardt - 165-177 Firm- and Drug-Specific Patterns of Generic Drug Payments by US Medicaid Programs: 1991–2008
by Christina Kelton & Lenisa Chang & Jeff Guo & Yan Yu & Edmund Berry & Boyang Bian & Pamela Heaton - 179-190 Impact of Early Versus Late Systemic Lupus Erythematosus Diagnosis on Clinical and Economic Outcomes
by Alan Oglesby & Caroline Korves & François Laliberté & Gregory Dennis & Sapna Rao & Ellison Suthoff & Robert Wei & Mei Duh - 191-201 That’s What Friends Are For: Adolescent Peer Social Status, Health-Related Quality of Life and Healthcare Costs
by Marlon Mundt & Larissa Zakletskaia - 203-217 Economic Evaluation of Using a Genetic Test to Direct Breast Cancer Chemoprevention in White Women with a Previous Breast Biopsy
by Linda Green & Tuan Dinh & David Hinds & Bryan Walser & Richard Allman - 219-230 Direct Medical Costs for Complications Among Children and Adults with Diabetes in the US Commercial Payer Setting
by Jason Yeaw & Shawn Halinan & Dionne Hines & Amy DeLozier & Magaly Perez & Mark Boye & Kristina Boye & Christopher Blanchette
February 2014, Volume 12, Issue 1
- 1-5 Remember the MaineRx
by Robert Kemp - 7-18 Propensity-Score Matching in Economic Analyses: Comparison with Regression Models, Instrumental Variables, Residual Inclusion, Differences-in-Differences, and Decomposition Methods
by William Crown - 19-32 Insulin Glargine in a Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review
by Ana Caires de Souza & Francisco de Acurcio & Augusto Guerra Júnior & Renata Rezende Macedo do Nascimento & Brian Godman & Leonardo Diniz - 33-40 A Critical Systematic Review of Budget Impact Analyses on Drugs in the EU Countries
by Katelijne Vooren & Silvy Duranti & Alessandro Curto & Livio Garattini - 41-49 The Cost Effectiveness of Implantable Cardioverter Defibrillators: A Systematic Review of Economic Evaluations
by Fotini Gialama & Panagiotis Prezerakos & Nikos Maniadakis - 51-58 Cost-Effectiveness Analysis of Clinically Indicated Versus Routine Replacement of Peripheral Intravenous Catheters
by Haitham Tuffaha & Claire Rickard & Joan Webster & Nicole Marsh & Louisa Gordon & Marianne Wallis & Paul Scuffham - 59-71 Economic Burden and Disparities in Healthcare Resource Use Among Adult Patients with Cardiac Arrhythmia
by Derek Tang & Adrienne Gilligan & Klaus Romero - 73-84 How Important Is Health Status in Defining Quality of Life for Older People? An Exploratory Study of the Views of Older South Australians
by Catherine Milte & Ruth Walker & Mary Luszcz & Emily Lancsar & Billingsley Kaambwa & Julie Ratcliffe - 85-93 Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in the United States
by Hongbo Yang & Paresh Chaudhari & Zheng-Yi Zhou & Eric Wu & Chad Patel & David Horn
December 2013, Volume 11, Issue 6
- 561-576 An Overview of the Health Economic Implications of Elective Caesarean Section
by Stavros Petrou & Kamran Khan - 577-592 The Economic Burden of Complications Occurring in Major Surgical Procedures: a Systematic Review
by Ajay Patel & Annika Bergman & Brigitte Moore & Ulf Haglund - 593-618 Cost-Effectiveness Analyses of Osteoarthritis Oral Therapies: a Systematic Review
by Ronald Wielage & Julie Myers & Robert Klein & Michael Happich - 619-637 Are the True Impacts of Adverse Events Considered in Economic Models of Antineoplastic Drugs? A Systematic Review
by Alison Pearce & Marion Haas & Rosalie Viney - 639-652 Preferences on Policy Options for Ensuring the Financial Sustainability of Health Care Services in the Future: Results of a Stakeholder Survey
by David Tordrup & Aris Angelis & Panos Kanavos - 653-660 Incremental Cost Effectiveness of Pharmacist-Managed Erythropoiesis-Stimulating Agent Clinics for Non-Dialysis-Dependent Chronic Kidney Disease Patients
by Sherrie Aspinall & Kenneth Smith & Chester Good & Xinhua Zhao & Roslyn Stone & Ivy Tonnu-Mihara & Francesca Cunningham - 661-670 A Model-Based Economic Evaluation of Improved Primary Care Management of Patients with Type 2 Diabetes in Australia
by Hossein Haji Ali Afzali & Jodi Gray & Justin Beilby & Christine Holton & Jonathan Karnon - 671-675 Direct Medical Cost and Glycemic Control in Type 2 Diabetic Saudi Patients
by Nora Almutairi & Khalid Alkharfy - 677-685 Impact of Delisting ARBs, Apart from Losartan, on ARB Utilisation Patterns in Denmark: Implications for Other Countries
by Ulrik Hesse & Brian Godman & Max Petzold & Andrew Martin & Rickard Malmström - 687-687 Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
by Dawn Lee & Patrick Thornton & Alexander Hirst & Lucie Kutikova & Robert Deuson & Nic Brereton - 689-689 Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
by Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres
October 2013, Volume 11, Issue 5
- 437-443 Generic Medicines: Solutions for a Sustainable Drug Market?
by Pieter Dylst & Arnold Vulto & Brian Godman & Steven Simoens - 445-456 Systematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing
by Ebenezer Tetteh & Stephen Morris - 457-469 Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
by Dawn Lee & Patrick Thornton & Alexander Hirst & Lucie Kutikova & Robert Deuson & Nic Brereton - 471-484 Does the Type of Provider and the Place of Residence Matter in the Utilization of Prenatal Ultrasonography? Evidence from Canada
by Harminder Guliani & Ardeshir Sepehri & John Serieux - 485-497 Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US
by Anju Parthan & Morgan Kruse & Nicole Yurgin & Joice Huang & Hema Viswanathan & Douglas Taylor - 499-507 Preferences for Colorectal Cancer Screening Techniques and Intention to Attend: a Multi-Criteria Decision Analysis
by J. Hummel & Lotte Steuten & C. Groothuis-Oudshoorn & Nick Mulder & Maarten IJzerman - 509-521 Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
by Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres - 523-529 Private Expenditures on Brand Name Prescription Drugs after Generic Entry
by Dahlia Balaban & Irfan Dhalla & Michael Law & Chaim Bell - 531-542 Economic Evaluation of Cardio inCode ® , a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment
by A. Ramírez de Arellano & A. Coca & M. de la Figuera & C. Rubio-Terrés & D. Rubio-Rodríguez & A. Gracia & A. Boldeanu & J. Puig-Gilberte & E. Salas - 543-552 Evolutions in Both Co-Payment and Generic Market Share for Common Medication in the Belgian Reference Pricing System
by Jessica Fraeyman & Moira Verbelen & Niel Hens & Guido Hal & Hans Loof & Philippe Beutels - 553-554 Comment on: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
by Hiltrud Liedgens & Rainer Henske - 555-557 Authors’ Reply to Liedgens and Henske: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
by Ronald Wielage & Megha Bansal & J. Andrews & Robert Klein & Michael Happich
August 2013, Volume 11, Issue 4
- 311-318 New Anti-Rebate Legislation in South Korea
by Su-Yeon Yu & Bong-Min Yang & Jin-Hyun Kim - 319-329 Quantifying Benefit–Risk Preferences for Medical Interventions: An Overview of a Growing Empirical Literature
by A. Brett Hauber & Angelyn Fairchild & F. Reed Johnson - 331-341 Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis
by Annie Hawton & James Shearer & Elizabeth Goodwin & Colin Green - 343-357 A Practical Approach for Calculating Reliable Cost Estimates from Observational Data: Application to Cost Analyses in Maternal and Child Health
by Jason Salemi & Meg Comins & Kristen Chandler & Mulubrhan Mogos & Hamisu Salihu - 359-368 The Trade-off Between Costs and Quality of Care in the Treatment of Psychosomatic Patients with Somatoform Pain Disorder
by Laura Haas & Tom Stargardt & Jonas Schreyoegg & Rico Schlösser & Burghard Klapp & Gerhard Danzer - 369-381 The Role of Financial Wellbeing, Sociopolitical Attitude, Self-Interest, and Lifestyle in One’s Attitude Toward Social Health Insurance
by Oliver Schnusenberg & Chung-Ping Loh & Katrin Nihalani - 383-393 Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden
by Brian Godman & Marie Persson & Jamilette Miranda & Peter Skiöld & Björn Wettermark & Corrado Barbui & Lars Gustafsson - 395-406 Compliance with Pharmacotherapy and Direct Healthcare Costs in Patients with Parkinson’s Disease: A Retrospective Claims Database Analysis
by Florent Richy & Guilhem Pietri & Kimberly Moran & Emmanuelle Senior & Lydia Makaroff - 407-413 Pre-Diagnosis Excess Acute Care Costs in Alzheimer’s Patients among a US Medicaid Population
by David Geldmacher & Noam Kirson & Howard Birnbaum & Sara Eapen & Evan Kantor & Alice Cummings & Vijay Joish - 415-425 A Comparison of the EQ-5D-3L and ICECAP-O in an Older Post-Acute Patient Population Relative to the General Population
by Leah Couzner & Maria Crotty & Richard Norman & Julie Ratcliffe - 427-435 Explaining the Health Costs Associated with Managing Intracranial Aneurysms in Italy
by Stefano Calciolari & Aleksandra Torbica & Rosanna Tarricone
June 2013, Volume 11, Issue 3
- 155-161 Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation
by Joanna Thorn & Joanna Coast & David Cohen & William Hollingworth & Martin Knapp & Sian Noble & Colin Ridyard & Sarah Wordsworth & Dyfrig Hughes - 163-180 Patient Preferences Versus Physicians’ Judgement: Does it Make a Difference in Healthcare Decision Making?
by Axel Mühlbacher & Christin Juhnke - 181-192 Cost Effectiveness of Fecal DNA Screening for Colorectal Cancer: A Systematic Review and Quality Appraisal of the Literature
by Mairead Skally & Paul Hanly & Linda Sharp - 193-203 Time Costs Associated with Informal Care for Colorectal Cancer: An Investigation of the Impact of Alternative Valuation Methods
by Paul Hanly & Alan Céilleachair & Mairead Skally & Eamonn O’Leary & Anthony Staines & Kanika Kapur & Patricia Fitzpatrick & Linda Sharp - 205-218 Multilevel Analysis of the Influence of Patients’ and General Practitioners’ Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France
by Sylvain Pichetti & Catherine Sermet & Brian Godman & Stephen Campbell & Lars Gustafsson - 219-236 Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective
by Ronald Wielage & Megha Bansal & J. Andrews & Robert Klein & Michael Happich - 237-249 Implications of a Data-Driven Approach to Treatment with Growth Hormone in Children with Growth Hormone Deficiency and Turner Syndrome
by Stefan Kaspers & Michael Ranke & Donald Han & Jane Loftus & Hartmut Wollmann & Anders Lindberg & Mathieu Roelants & Joris Kleintjens - 251-258 Community-Acquired Pneumonia Episode Costs by Age and Risk in Commercially Insured US Adults Aged ≥50 Years
by Reiko Sato & Gabriel Gomez Rey & Stephanie Nelson & Brett Pinsky - 259-274 A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use
by David Price & Yumi Asukai & Jaithri Ananthapavan & Bill Malcolm & Amr Radwan & Ian Keyzor - 275-286 Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs
by Juliana Meyers & Yanni Yu & James Kaye & Keith Davis - 287-298 A Pilot Discrete Choice Experiment to Explore Preferences for EQ-5D-5L Health States
by Richard Norman & Paula Cronin & Rosalie Viney - 299-304 Economic Burden of Non-Cystic Fibrosis Bronchiectasis in the First Year after Diagnosis from A US Health Plan Perspective
by Vijay Joish & Monica Spilsbury-Cantalupo & Elisabeth Operschall & Ba Luong & Susan Boklage - 305-305 Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison
by Carlos Alatorre & Virginia Haynes & Douglas Faries & Himanshu Upadhyaya & Douglas Kelsey - 307-307 Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”
by M. Erder & Jipan Xie & James Signorovitch & Kristina Chen & Paul Hodgkins & Mei Lu & Eric Wu & Vanja Sikirica - 309-309 Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder
by M. Erder & Jipan Xie & James Signorovitch & Kristina Chen & Paul Hodgkins & Mei Lu & Eric Wu & Vanja Sikirica
April 2013, Volume 11, Issue 2
- 85-93 Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases
by Hossein Haji Ali Afzali & Jodi Gray & Jonathan Karnon - 95-106 The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia
by Evanthia Achilla & Paul McCrone - 107-117 Cost-Effectiveness Analysis of 3-D Computerized Tomography Colonography Versus Optical Colonoscopy for Imaging Symptomatic Gastroenterology Patients
by Manuel Gomes & Robert Aldridge & Peter Wylie & James Bell & Owen Epstein - 119-128 Annual All-Cause Healthcare Costs Among Influenza Patients With and Without Influenza-Related Complications
by Sudeep Karve & Derek Misurski & Guillermo Herrera-Taracena & Keith Davis - 129-138 Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma
by Lionel Perrier & Anne Lefranc & David Pérol & Philippe Quittet & Aline Schmidt-Tanguy & Carole Siani & Christian Peretti & Bertrand Favier & Pierre Biron & Philippe Moreau & Jacques Bay & Séverine Lissandre & Fabrice Jardin & Daniel Espinouse & Catherine Sebban